Margaret M. Sedensky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margaret M. Sedensky has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Philip G. Morgan
Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington
6 shared publications Phil G. Morgan
Seattle Children's Research Institute, University of Washington, Seattle, Washington.,.
3 shared publicationsPhilip G. Morgan
3 shared publications- Ernst-Bernhard Kayser
Affiliation: Center for Developmental Therapeutics, Seattle Children's Research Institute, Seattle, Washington, United States of America
2 shared publications - Jon A. Gangoiti
UCSD Biochemical Genetics and Metabolomics Laboratory and
2 shared publications Michael J. Keogh
2 shared publications
Latest Publications
- Open Access
- 8 March 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (5)
Leukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndrome
Symmetric, progressive, necrotizing lesions in the brainstem are a defining feature of Leigh syndrome (LS). A mechanistic understanding of the pathogenesis of these lesions has been elusive. Here, we report that leukocyte proliferation is causally involved in the pathogenesis of LS. Depleting leukocytes with a colony-stimulating factor 1 receptor inhibitor disrupted disease progression, including suppression of CNS lesion formation and a substantial extension of survival. Leukocyte depletion rescued diverse symptoms, including seizures, respiratory center function, hyperlactemia, and neurologic sequelae. These data reveal a mechanistic explanation for the beneficial effects of mTOR inhibition. More importantly, these findings dramatically alter our understanding of the pathogenesis of LS, demonstrating that immune involvement is causal in disease. This work has important implications for the mechanisms of mitochondrial disease and may lead to novel therapeutic strategies.
- 8 March 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (5)
Open AccessLeukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndrome
Symmetric, progressive, necrotizing lesions in the brainstem are a defining feature of Leigh syndrome (LS). A mechanistic understanding of the pathogenesis of these lesions has been elusive. Here, we report that leukocyte proliferation is causally involved in the pathogenesis of LS. Depleting leukocytes with a colony-stimulating factor 1 receptor inhibitor disrupted disease progression, including suppression of CNS lesion formation and a substantial extension of survival. Leukocyte depletion rescued diverse symptoms, including seizures, respiratory center function, hyperlactemia, and neurologic sequelae. These data reveal a mechanistic explanation for the beneficial effects of mTOR inhibition. More importantly, these findings dramatically alter our understanding of the pathogenesis of LS, demonstrating that immune involvement is causal in disease. This work has important implications for the mechanisms of mitochondrial disease and may lead to novel therapeutic strategies.
- 28 April 2018
- Published by Cambridge University Press (CUP)
Clinical Mitochondrial Medicine
Mitochondrial disorders are a highly diverse group of conditions that can affect almost every major system in the human body, often mimicking common disorders. This clinical variety often results in prolonged and often dangerous, diagnostic delays. This textbook provides a practical framework, to enable rapid identification, investigation, and treatment of mitochondrial disorders across the spectrum of clinical practice. Clinically relevant and comprehensive, this textbook employs a system- and case-based approach for practitioners of all levels. It focuses on major phenotypic features, syndromes and management relevant for clinical practice, within a broad overview of the field. This interactive book supports readers with knowledge distilled from over 20 internationally recognized, mitochondrial experts.
- 28 April 2018
- Published by Cambridge University Press (CUP)
Clinical Mitochondrial Medicine
Mitochondrial disorders are a highly diverse group of conditions that can affect almost every major system in the human body, often mimicking common disorders. This clinical variety often results in prolonged and often dangerous, diagnostic delays. This textbook provides a practical framework, to enable rapid identification, investigation, and treatment of mitochondrial disorders across the spectrum of clinical practice. Clinically relevant and comprehensive, this textbook employs a system- and case-based approach for practitioners of all levels. It focuses on major phenotypic features, syndromes and management relevant for clinical practice, within a broad overview of the field. This interactive book supports readers with knowledge distilled from over 20 internationally recognized, mitochondrial experts.
- 28 April 2018
- Published by Cambridge University Press (CUP)
- p. 141-153
Respiratory Medicine and Anesthesiology
- 28 April 2018
- Published by Cambridge University Press (CUP)
- p. 141-153
Respiratory Medicine and Anesthesiology
- 1 January 2018
- Published by Elsevier
- Vol. 602, 133-151
Approaches to Anesthetic Mechanisms: The C. elegans Model
- 1 January 2018
- Published by Elsevier
- Vol. 602, 133-151
Approaches to Anesthetic Mechanisms: The C. elegans Model
- 1 August 2014
- Published by Elsevier in Experimental Gerontology
- Vol. 56, 245-255
Effects of the mitochondrial respiratory chain on longevity in C. elegans
- 1 August 2014
- Published by Elsevier in Experimental Gerontology
- Vol. 56, 245-255
Effects of the mitochondrial respiratory chain on longevity in C. elegans
- 1 November 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (6) , 915
Capacity for oxidative phosphorylation does not decline with age in mitochondria from ndufs4 knockout mice
- 1 November 2013
- Published by Elsevier in Mitochondrion
- Vol. 13 (6) , 915
Capacity for oxidative phosphorylation does not decline with age in mitochondria from ndufs4 knockout mice
- 1 October 2013
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 119 (4) , 995-996
The Power of Unbiased Genetic Screens to Discover Novel Anesthetic Targets
We are writing in response to Dr. Forman’s1 editorial “The Expanding Genetic Toolkit for Exploring Mechanisms of General Anesthesia” in the April issue of Anesthesiology. Dr. Forman covers many excellent points about the use of genetics in understanding anesthetic mechanisms. However, we think that he has overlooked, and perhaps unintentionally discounted, the key ability of an unbiased forward genetic screen to study anesthetic action. A forward screen generates mutations randomly and then looks for those mutations that affect a particular trait. Its unique beauty or power is that it can discover novel mechanisms that would not be found if one presupposed to know an anesthetic target. Forward genetic screens have identified plausible possible targets of volatile anesthetics. They have included leak channels,2 neurotransmitter release machinery,3 and mitochondria.4 All three possibilities have been shown to be directly affected by volatile anesthetics and have been shown to affect anesthetic sensitivity in multiple organisms.5–7 By dismissing mitochondrial complex I as a possible anesthetic target, it seems that Dr. Forman does not appreciate the full power of a genetic approach to solve difficult problems.
- 1 October 2013
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 119 (4) , 995-996
The Power of Unbiased Genetic Screens to Discover Novel Anesthetic Targets
We are writing in response to Dr. Forman’s1 editorial “The Expanding Genetic Toolkit for Exploring Mechanisms of General Anesthesia” in the April issue of Anesthesiology. Dr. Forman covers many excellent points about the use of genetics in understanding anesthetic mechanisms. However, we think that he has overlooked, and perhaps unintentionally discounted, the key ability of an unbiased forward genetic screen to study anesthetic action. A forward screen generates mutations randomly and then looks for those mutations that affect a particular trait. Its unique beauty or power is that it can discover novel mechanisms that would not be found if one presupposed to know an anesthetic target. Forward genetic screens have identified plausible possible targets of volatile anesthetics. They have included leak channels,2 neurotransmitter release machinery,3 and mitochondria.4 All three possibilities have been shown to be directly affected by volatile anesthetics and have been shown to affect anesthetic sensitivity in multiple organisms.5–7 By dismissing mitochondrial complex I as a possible anesthetic target, it seems that Dr. Forman does not appreciate the full power of a genetic approach to solve difficult problems.
- 31 July 2011
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 132 (6-7) , 331-339
The role of DMQ9 in the long-lived mutant clk-1
- 31 July 2011
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 132 (6-7) , 331-339
The role of DMQ9 in the long-lived mutant clk-1
- Open Access
- 1 December 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (52) , 40724-40731
Mutations in Mitochondrial Complex III Uniquely Affect Complex I in Caenorhabditis elegans
- 1 December 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (52) , 40724-40731
Open AccessMutations in Mitochondrial Complex III Uniquely Affect Complex I in Caenorhabditis elegans
- 1 June 2009
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 130 (6) , 370-376
The effect of different ubiquinones on lifespan in Caenorhabditis elegans
- 1 June 2009
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 130 (6) , 370-376
The effect of different ubiquinones on lifespan in Caenorhabditis elegans